Foghorn Therapeutics (FHTX) outlined its objectives for 2025 on Monday, including advancing its inhibitor and degrader program trials.
The company said it will continue to enroll and dose patients in a phase 1 trial of FHD-909 to treat solid tumors. It will also present preclinical combination data for FHD-909 with pembrolizumab and KRAS inhibitors at the American Association for Cancer Research's annual meeting in April, the company said.
"We are continuing to advance our Selective CBP degrader and our Selective EP300 degrader, which are both implicated in a wide range of cancers," Chief Executive Adrian Gottschalk said in a statement.
Foghorn said that as of the end of 2024, it had $243.8 million cash, cash equivalents and marketable securities that will provide a cash runway into 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.